within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AG02_Efalizumab;

model Efalizumab
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.722222222222222e-07,
    adminDuration = 600,
    adminMass = 1 / 1000000,
    adminCount = 1,
    Vd = 0.00023,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.000313,
    k12 = 3.3055555555555566e-07,
    k21 = 3.3055555555555566e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Efalizumab</td></tr><tr><td>ATC code:</td><td>L04AG02</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.23</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.014</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Efalizumab is a humanized monoclonal IgG1 antibody that binds to CD11a, a subunit of leukocyte function-associated antigen-1 (LFA-1). It was used for the treatment of moderate to severe chronic plaque psoriasis. Due to safety concerns related to progressive multifocal leukoencephalopathy (PML), efalizumab was withdrawn from the market and is not approved or used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult psoriasis patients after subcutaneous administration.</p><h4>References</h4><ol><li><p>Sun, YN, et al., &amp; Bruno, RA (2005). Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. <i>Journal of clinical pharmacology</i> 45(4) 468–476. DOI:<a href=\"https://doi.org/10.1177/0091270004272731\">10.1177/0091270004272731</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15778428/\">https://pubmed.ncbi.nlm.nih.gov/15778428</a></p></li><li><p>Mortensen, DL, et al., &amp; Joshi, A (2005). Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. <i>Journal of clinical pharmacology</i> 45(3) 286–298. DOI:<a href=\"https://doi.org/10.1177/0091270004270260\">10.1177/0091270004270260</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15703364/\">https://pubmed.ncbi.nlm.nih.gov/15703364</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L04AG02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Efalizumab;
